Aminoalkylindole

Aminoalkylindoles (AAIs) are a family of cannabinergic compound that act as a cannabinoid receptor agonist. They were invented by pharmaceutical company Sterling-Winthrop in the early 1990s as potential nonsteroidal anti-inflammatory agents.[1]

Legality

Aminoalkylindole are now commonly found in synthetic cannabis designer drugs.[2]

In the United States, the DEA added the aminoalkylindole JWH-200 to Schedule I of the Controlled Substances Act on 1 March 2011 for 12 months.[2][3]

gollark: https://osmarks.tk/nemc/
gollark: In this country the government has "computing" lessons which involve just teaching people Scratch, which annoyed me enough that I wrote a blog post criticizing this.
gollark: It would also be nice if people actually knew anything about networking.
gollark: I fear that some sort of computer troubleshooting class may just end up teaching people to blindly try one specific thing they learned instead of... actually problem-solving. Which would admittedly be better than now.
gollark: People just see an error of some sort, and immediately their brain shuts down, even if it specifies what to do about it.

References

  1. Emmanuel S. Onaivi (2006). Marijuana and Cannabinoid Research: Methods and Protocols. Springer. pp. 128–. ISBN 978-1-59259-999-8.
  2. "Synthetic Cannabinoids". American Association for Clinical Chemistry. 2013-02-01. Retrieved 2013-11-17.
  3. "Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I". Federal Register. 2011-03-01. Retrieved 2013-11-17.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.